Key result
Adjusted-dose oral anticoagulants significantly reduced the risk of all stroke compared with antiplatelet therapy in patients with non-valvular AF (OR 0.68; 95% CI 0.54-0.85).
Why the study?
Do adjusted-dose oral anticoagulants reduce stroke and major vascular events compared to antiplatelet therapy in patients with non-valvular atrial fibrillation and no prior stroke or TIA?
Population
9,598 patients with chronic non-valvular atrial fibrillation and no history of stroke or transient ischemic…
Comparison
Adjusted-dose oral anticoagulant treatment for… vs Antiplatelet therapy
Design
Meta-analysis
Follow-up
mean 1.9 years/participant
Authors
Loading...
Supports adjusted-dose anticoagulation over antiplatelet therapy for stroke prevention in non-valvular AF; confirms benefit from eight RCTs in patients without prior stroke/TIA.
Meta-Analysis (n=9,598)
Yes
Do adjusted-dose oral anticoagulants reduce stroke and major vascular events compared to antiplatelet therapy in patients with non-valvular atrial fibrillation and no prior stroke or TIA?
Odds Ratio: 0.68 (95% CI 0.54–0.85)
Adjusted-dose oral anticoagulants reduce the risk of stroke by about one third compared to antiplatelet therapy in patients with non-valvular AF and no prior stroke/TIA, despite an increased risk of intracranial hemorrhage.
Aguilar et al. (2007) conducted a meta-analysis in Non-valvular atrial fibrillation (n=9,598). Adjusted-dose oral anticoagulants (warfarin) vs. Antiplatelet therapy (aspirin 75 to 325 mg/day) was evaluated on All stroke (OR 0.68, 95% CI 0.54 to 0.85). Adjusted-dose oral anticoagulants significantly reduced the risk of all stroke compared with antiplatelet therapy in patients with non-valvular AF (OR 0.68; 95% CI 0.54-0.85).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: